21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate CancerDrug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit […]